Officials at iXCells Biotechnologies say the company agreed to integrate Rosebud Biosciences’ organoid generation and characterization expertise into its existing iPSC solutions to enable access to complex 3D human systems that better represent tissue-level biology and simulate therapeutic response.
The combined workflow brings together iXCells’ scalable, modular iPSC platform, iPSCore with Rosebud’s AI-driven organoid platform, designed to generate scalable, reproducible human tissue data for drug discovery and safety assessment, explained Steve Smith, CEO of iXCells Biotechnologies. Together, the technologies offer researchers more complete and biologically representative model systems for understanding disease mechanisms and drug safety, he added.
Organoids have become an important component of translational research strategies, particularly for evaluating drug toxicity and tissue-specific responses.
“This collaboration enhances our end-to-end platform and expands our ability to deliver next-generation models that reflect human biology with greater depth and accuracy,” continued Smith. “In areas such as rare diseases, where predicting human-specific safety and response earlier can significantly impact development timelines and patient outcomes, these integrated systems provide critical insight. This partnership reflects the strategic direction we are taking as iXCells scales its platform to support more complex, translationally focused programs for our partners.”
“Our partnership with iXCells allows us to make advanced organoid systems more accessible to researchers who need models that better represent human biology,” noted Kitch Wilson, CEO and co-founder of Rosebud Biosciences. “By combining our complementary strengths, we can support deeper exploration of disease biology and help drive the next generation of therapeutic discovery.”
The post iXCells and Rosebud Biosciences Partner on Organoid-Based Rare Disease Models appeared first on GEN – Genetic Engineering and Biotechnology News.
